Investigation of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics of Single Administrations of NNC9733-0001 in Healthy Participants and in Participants With Type 2 Diabetes

What this Trial Is About

Researchers are evaluating a new medicine called NNC9733-0001 for its potential to help people with type 2 diabetes manage high blood sugar levels. The study also includes healthy participants to compare safety and tolerance. This Phase 1 trial aims to assess how safe and tolerable the medicine is when given as a single dose. Participants will be randomly assigned to receive either the study medicine or a placebo, which contains no active medicine. The dose strength is determined by when the participant enters the study, and the medicine is given as one or up to four injections around the abdomen by medical staff. The total study duration is about 40 weeks 10 months. During the study, participants will be monitored for side effects and any low blood sugar events from dosing until the end of the study at week 36. Blood samples will be collected to measure how the medicine behaves in the body over 48 hours after dosing. Participants will have regular assessments including physical exams, vital signs, ECGs, and laboratory tests to track safety and how the medicine is processed. The study includes healthy volunteers and people with type 2 diabetes aged 18 to 64 years.

A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 Diabetes